Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.79 |
| ▸ | TEC | P42680 | 3/20 | 0.57 |
| ▸ | LCK | P06239 | 3/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
| ▸ | TXK | P42681 | 1/20 | 0.54 |
| ▸ | BLK | P51451 | 1/20 | 0.54 |
| ▸ | BMX | P51813 | 1/20 | 0.54 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.54 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.53 |
| ▸ | ITK | Q08881 | 1/20 | 0.53 |
| ▸ | CD69 | Q07108 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30111816 | 1.00 | BTK (0.79) | BTKTECLCKERBB2TXK | |
| SCHEMBL18286051 | 1.00 | BTK (0.79) | BTKTECLCKERBB2TXK | |
| SCHEMBL30866994 | 0.87 | BTK (0.69) | BTKTECEGFRCD69 | |
| SCHEMBL18285658 | 0.87 | BTK (0.69) | BTKTECEGFRCD69 | |
| SCHEMBL24832598 | 0.86 | BTK (0.67) | BTKTECEGFRCD69 | |
| SCHEMBL18285617 | 0.86 | BTK (0.72) | BTKTECEGFRCD69 | |
| SCHEMBL18285620 | 0.86 | BTK (0.72) | BTKTECEGFRCD69 | |
| SCHEMBL18285712 | 0.86 | BTK (0.68) | BTKTECEGFRCD69 | |
| SCHEMBL18285514 | 0.86 | BTK (0.70) | BTKTECLCKEGFRITK | |
| SCHEMBL18285544 | 0.86 | BTK (0.68) | BTKTECEGFRCD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2023-05-18 | — | — | US | claimed |
| EP-3912979-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2021-11-24 | — | — | EP | claimed |
| US-20210171526-A1 | Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-06-10 | — | — | US | claimed |
| EP-3303334-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-06-02 | — | — | EP | claimed |
| US-20180162861-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2018-06-14 | — | — | US | claimed |
| EP-3303334-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2018-04-11 | — | — | EP | claimed |
| US-20170129890-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2017-05-11 | — | — | US | claimed |
| WO-2016196840-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2016-12-08 | — | — | WO | claimed |
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4112618-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-3912979-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| US-9688676-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688676-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688676-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170129890-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170129890-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170129890-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171526-A1 | Tyrosine Kinase Inhibitors | BTK, LYN, SYK | BTK 1/4885TEC 12/4885LCK 4/4885 |
| US-20180162861-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | BTK 1/4885TEC 12/4885LCK 4/4885 |
| US-20170129890-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | BTK 1/4885TEC 12/4885LCK 4/4885 |
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | BTK 1/4885TEC 12/4885LCK 4/4885 |
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | BTK, LYN, SYK | BTK 1/4885TEC 12/4885LCK 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.